Levy, MD, JD is a board-certified cardiologist
For Dihexa to progress in Alzheimer's research, several conditions would need to be met: Earlier intervention: Testing in cognitively normal individuals at high risk, or mild cognitive impairment, rather than established dementia Bioavailability optimization: Development of oral formulations with superior brain penetration, or better-tolerated intravenous regimens Combination approaches: Testing Dihexa alongside amyloid-targeting drugs or tau-focused therapeutics Mechanism refinement: Understanding which aspects of HGF signalling are beneficial versus which drive cancer risk concerns Patient stratification: Identifying subgroups (by genetics, biomarker status, disease stage) most likely to respond Dose optimization: The LIFT-AD trial used specific doses
I caution them about getting them from a quality source
There is no universal winner because both options work, just for different reasons and on different timelines
Pyridoxamine phosphate is a common form of vitamin B6 in animal-sourced foods
Purity & Documentation Data Sheet (275 KB) SDS (392 KB) English - EN (392 KB) Franais - FR (392 KB) Deutsch - DE (392 KB) Norwegian - NO (392 KB) Espaol - ES (392 KB) Swedish - SV (392 KB) Italian - IT (392 KB) Korean - KR (392 KB) Portuguese - PT (392 KB) Handling Instructions (2659 KB) References [1]